All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer lines. Strikingly, the two drugs strongly synergized in cytotoxicity in tumor cells lacking wild-type p53. Mechanistically, ganetespib and carboplatin in combination, but not individually, induced persistent DNA damage causing massive global chromosome fragmentation. Live-cell microscopy revealed chromosome fragmentation occurring to a dramatic degree when cells condensed their chromatin in preparation for mitosis, followed by cell death in mitosis or upon aberrant exit from mitosis. HSP90 inhibition caused the rapid decay of key components of the Fanconi anemia pathway required for repair of carboplatin-induced interstrand crosslinks (ICLs), as well as of cell cycle checkpoint mediators. Overexpressing FancA rescued the DNA damage induced by the drug combination, indicating that FancA is indeed a key client of Hsp90 that enables cancer cell survival in the presence of ICLs. Conversely, depletion of nuclease DNA2 prevented chromosomal fragmentation, pointing to an imbalance of defective repair in the face of uncontrolled nuclease activity as mechanistic basis for the observed premitotic DNA fragmentation. Importantly, the drug combination induced robust antitumor activity in xenograft models, again accompanied with depletion of FancA. In sum, our findings indicate that ganetespib strongly potentiates the antitumor efficacy of carboplatin by causing combined inhibition of DNA repair and cell cycle control mechanisms, thus triggering global chromosome disruption, aberrant mitosis and cell death.
All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer lines. Strikingly, the two drugs strongly synergized in cytotoxicity in tumor cells lacking wild-type p53. Mechanistically, ganetespib and carboplatin in combination, but not individually, induced persistent DNA damage causing massive global chromosome fragmentation. Live-cell microscopy revealed chromosome fragmentation occurring to a dramatic degree when cells condensed their chromatin in preparation for mitosis, followed by cell death in mitosis or upon aberrant exit from mitosis. HSP90 inhibition caused the rapid decay of key components of the Fanconi anemia pathway required for repair of carboplatin-induced interstrand crosslinks (ICLs), as well as of cell cycle checkpoint mediators. Overexpressing FancA rescued the DNA damage induced by the drug combination, indicating that FancA is indeed a key client of Hsp90 that enables cancer cell survival in the presence of ICLs. Conversely, depletion of nuclease DNA2 prevented chromosomal fragmentation, pointing to an imbalance of defective repair in the face of uncontrolled nuclease activity as mechanistic basis for the observed premitotic DNA fragmentation. Importantly, the drug combination induced robust antitumor activity in xenograft models, again accompanied with depletion of FancA. In sum, our findings indicate that ganetespib strongly potentiates the antitumor efficacy of carboplatin by causing combined inhibition of DNA repair and cell cycle control mechanisms, thus triggering global chromosome disruption, aberrant mitosis and cell death. HSP90 inhibitors represent promising agents in cancer treatment. They destabilize a number of HSP90 client proteins required for cancer cell proliferation and survival, and increase proteotoxic stress. 1 Among these clients are tumor drivers such as mutant p53 (ref. 2) and MIF, 3 but also cell cycle regulators like Wee1(ref. 4 ) and Chk1, 5 as well as DNA repair proteins such as those governing the Fanconi Anemia DNA repair pathway. 6 This provides a strong rationale for HSP90 inhibitors in cancer therapy 7 and raises the possibility that HSP90 inhibitors can be used in combination with DNAdamaging chemotherapeutics. 8 Ovarian cancer is among the most common gynecological tumor types and carries the worst prognosis. HSP90 is highly expressed in advanced ovarian carcinoma 9 and thus constitutes a potential therapeutic drug target. 10 In support, HSP90 inhibitors were found effective against ovarian cancer in preclinical models, [11] [12] [13] [14] alone or in combination with conventional chemotherapy. 15, 16 Carboplatin is the key component of all current first-line therapies for ovarian carcinoma. However, while initially often responding with regression, most tumors relapse and develop resistance within less than a year. 17, 18 Like other platinum compounds, carboplatin acts by forming crosslinks within DNA. 17 Platinum compounds form intrastrand DNA lesions but also interstrand crosslinks (ICLs) by covalently linking opposite DNA strands. Such ICLs represent major obstacles to the DNA replication fork 19 and are therefore considered the principal toxic lesion of carboplatin's mode of action. The ICLs can only be removed by a sophisticated DNA repair systemthe Fanconi Anemia pathway (FA) -which consists of numerous protein components acting within complexes. FAmediated DNA repair operates by orchestrated excision of the crosslinked portion of the DNA. During this process, one template strand of the replicating DNA is temporarily cleaved, leaving a double-strand DNA break (DSB) after completion of the daughter strand synthesis on both sides. Under normal circumstances, the break is subsequently repaired by homologous recombination repair. Identifying ways of targeting the FA pathway may represent a viable sensitization strategy towards ICL-inducing agents such as platinum compounds.
As the HSP90 inhibitor ganetespib destabilizes a number of DNA repair factors and cell cycle regulators, we asked whether it also perturbs the capability of tumor cells to survive ICLs, thereby potentially leading to synergistic tumor cell killing with carboplatin. Our results indicate that carboplatin and ganetespib strongly synergize to reduce the viability of most ovarian cancer cell lines. Strikingly, upon combined treatment, a large fraction of ovarian cancer cells undergo dramatic DNA fragmentation before entering mitosis. We show that degradation of FancA by HSP90 inhibition and the 
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Untransformed cells Figure 1 For caption see page on 302 21 to calculate the combination index (CI), we found that 13 out of the 15 lines displayed synergistic effects of the two drugs at both concentrations (CIo1), while the remaining 2 lines showed additive drug cooperation at IC50 (CI = 1) and true synergism at IC25. Importantly, combined treatment induced cytotoxic effects in 60-80% of all tumor cells as shown by the 'Fa' value (fraction affected; Figure 1a) . Moreover, the synergistic effect of ganetespib and carboplatin caused increased induction of apoptosis compared with single drug treatment, shown by Annexin V/7-AAD staining using flow cytometry ( Figure 1c ) and immunoblot analysis of caspase-mediated PARP cleavage (Figure 1d ). Contrasting results were obtained with two non-transformed cell lines (RPE-Tert and MCF10a cells). Here, the two drugs were antagonistic (Figures 1a and b) , and unable to induce detectable apoptosis in RPE-Tert cells (Figure 1d ). Similar results were obtained when ovarian cancer cell lines were treated with cisplatin, the original platinum drug, in combination with ganetespib ( Supplementary Figures S1C and S1D) . The cell proliferation rates failed to correlate positively with the CIs, (Supplementary Figure S1E) , thus largely excluding a possible bias from slowly replicating cells to explain chemoresistance. Of note, however, p53-proficiency did correlate with resistance towards the drug combination (Supplementary Figure S1F) . Lack of drug synergy in p53-proficient cell lines could not be explained by p53-dependent differences in cell proliferation (Supplementary Figures S1G and S1K). Instead, we hypothesized that p53 might protect cells through a p21-mediated cell cycle checkpoint. And indeed, loss of p53 as well as loss of its downstream target p21 re-established drug synergism in (colon cancer-derived) HCT116 cells 22 (Supplementary Figure S1H) , accompanied by increased γH2AX levels and accumulation of mitotically arrested cells (Supplementary Figures S1I and S1J) . Similarly, shRNA-mediated depletion of wild-type p53 in the ovarian cancer-derived cell line A2780 led to increased levels of the G2 checkpoint regulator cyclin B1, 23 as well as decreased levels of carboplatin-induced DDB2 (Supplementary Figure S1L) , a p53-inducible gene product involved in mediating carboplatin resistance. 24 In conclusion, ganetespib and platinum act in a synergistic manner to induce death in the majority of ovarian carcinoma cells but not in non-transformed and/or p53-proficient cells.
The combination of carboplatin with ganetespib leads to accumulation of persistent DNA damage in ovarian cancer cells. Carboplatin, like other DNA-crosslinking agents, exerts its cytotoxic effects mainly through the induction of DNA damage, in particular ICLs. We therefore asked whether ganetespib might enhance this damage and the cellular response to it. Immunostaining of phosphorylated histone H2AX (γH2AX) revealed that this was indeed the case. At concentrations where single agents enhanced γH2AX levels only moderately or not at all, the combination of ganetespib and carboplatin led to a strong increase of γH2AX, as determined by quantitative immunofluorescence analysis (Figures 2a and b) and by immunoblot analysis (Figure 2c ). In the latter case, phosphorylated Kap1 (pKap1) mirrored the accumulation of γH2AX upon combined treatment. The global levels of ATM and Chk2 were not increased but rather diminished by ganetespib, at least at 48 h post treatment, arguing that the enhanced phosphorylation of H2AX and Kap1 is due to enhanced signaling activity, but not simply due to the sheer accumulation of kinases within this pathway (Supplementary Figure S2) . Moreover, the detection of phosphorylated RPA32 (pRPA32, Figure 2c ) suggested the presence of single-stranded DNA (ssDNA) replication Table S1 ) for 48 h in the presence of 20 μM zVAD to prevent false positive staining due to apoptosis induction. (b) Quantification of the average phosphorylated H2AX signal intensity by high-content microcopy shown in a. In all cases, the damage signal was highest with the drug combination. Significance was determined by the Student's t-test and the P-value is shown by asterisks (***P-valueo0.001) (c) Signaling intermediates of the DNA damage response such as phosphorylated Kap1 (pKap1), phosphorylated H2AX (γH2AX) and phosphoryated RPA32 (S4/S8) are highest with the drug combination. pRPA32 marks single-stranded DNA, as occurring during replicative stress. Immunoblot analysis upon treatment for 24 h without zVAD. (b and c) Drug concentrations as in Figure 1c and Supplementary Table S1 accumulated in G1 and S phase (Supplementary Figure S3A) , and later in G2 (Supplementary Figure S3B) , but failed to enter mitosis ( Figure 3a) . However, treatment with the HSP90 inhibitor, alone or in combination with carboplatin, led to the accumulation of cells in mitosis, as indicated by immunostaining of phosphorylated histone 3 (phospho-H3 Ser10; Figure 3a ). In contrast, p53-proficient Figure S3B) , possibly due to p53-mediated G1 arrest, correlating with their failure to undergo apoptosis upon combined treatment (Supplementary Figure S1E) . In addition, the checkpoint kinases Wee1 and Chk1, both required for a functional G2/M checkpoint [25] [26] [27] [28] and both dependent on intact HSP90 function, 4,5 nearly disappeared upon HSP90 Ovcar-5 cells Figure S3C ). To probe the relevance of ganetespibmediated destabilization of Wee1 and Chk1, we transiently overexpressed each of these kinases, followed by treatment with ganetespib and/or carboplatin. However, as this did not detectably alter the response to the two drugs (Supplementary Figure S3D-H) , we propose that degradation of additional HSP90 clients that regulate the cell cycle, such as Cdc2 (ref. 29 ) and Cdc25c, 30 may also contribute to the combined drug efficacy. In any case, the combined treatment of ovarian cancer cells with carboplatin and HSP90 inhibitor triggers the accumulation of damaged cells in mitosis, apparently by destabilizing a variety of cell cycle regulators.
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Ganetespib in combination with carboplatin induces massive accumulation of small condensed chromosomal fragments. To better understand the cell fate that follows DNA damage in response to combined treatment, we performed chromosome analysis by metaphase spreads. In response to ganetespib/carboplatin treatment, but not upon single drug treatment, dramatic fragmentation of chromosomes was observed (Supplementary Figures S4A, S4B) . Caspase inhibition by additional treatment with the caspase inhibitor zVAD did not alleviate this fragmentation, indicating that it is not a result of apoptosis induction (Figures 4a  and b) . Of note, the numbers of visible crosslinks and radials induced by carboplatin were not increased by ganetespib. Importantly, this fragmentation was observed in all the chromosomes within a cell and in more than 90% of all metaphases (Figure 4c; Supplementary Figure S4C ).
DNA fragmentation precedes chromatin condensation upon combined ganetespib and carboplatin. To assess whether the DNA fragmentation occurs before or after entry into mitosis, the cells were treated with the two drugs alone or in combination, and TUNEL staining performed in the presence of zVAD, to detect DNA breaks that were not caused by apoptosis. This revealed the appearance of DNA breaks in the majority of cells only on drug combination (Figure 5a ). Live cell imaging provided a more detailed insight into the fate of cells that undergo chromosome fragmentation.
Specifically, treated cells entered mitosis and condensed their chromosomes. However, owing to persistent DNA breaks, the chromosomes showed massive fragmentation and were scattered throughout the cell, thereby preventing proper chromosome alignment and faithful execution of mitosis. Subsequently, a minor fraction of cells died in mitosis, whereas the majority of cells de-condensed their chromatin and exited from mitosis without undergoing cell division. Those cells were characterized by irregularly shaped nuclei and micronuclei that were formed on the unscheduled exit from mitosis. Ultimately, most of these cells died in the subsequent interphase (Figures 5b and c ; Supplementary Videos S1-S3). Thus, the synergistic effect of the two drugs can be explained, at least in part, by severe, persistent and unrepaired damage to tumor cell DNA. This in turn leads to premitotic DNA fragmentation followed either by immediate death or by uncontrolled transition to mitosis and subsequent cell death.
Ganetespib synergizes with other ICL-inducing agents and induces rapid degradation of Fanconi Anemia pathway components. Next, we found that key components of the ICL repair machinery and Fanconi Anemia (FA) pathway, such as FancA, BLM and ubiquitinated FancD2 were rapidly degraded in response to ganetespib treatment (Figure 6a ; Supplementary Figure S6A ). Even as little as 1 h of treatment with ganetespib was sufficient to induce FancA degradation, and when combined with 48 h of carboplatin treatment led to the increased accumulation of γH2AX and cleaved PARP1 in Ovcar-5 cells (Figure 6b ). In the case of FancD2, carboplatin led to the appearance of a second protein species with higher molecular weight ('FancD2-L'; Figure 6a ), corresponding to monoubiquitinated FancD2 that is induced by the upstream components of the pathway upon activation. 31 When carboplatin was combined with ganetespib, FancD2 was not only reduced in its total levels, but the upper band corresponding to ubiquitinated FancD2 disappeared completely. Thus, both the key components and key functionality of the FA pathway are compromised by HSP90 inhibition. Caspase inhibition did not detectably affect the ganetespib-induced loss of FancA and FancD2 levels (Supplementary Figure S6B) . This was in line with unchanged PARP1 levels (Supplementary Figure S6B) . Mitomycin C, a chemically unrelated ICLinducing agent, also synergized with ganetespib in its toxicity towards ovarian cancer cells (Figure 6c ), similar to Ganetespib and carboplatin strongly synergize in the inhibition of tumor xenografts in vivo. Next, we tested whether the synergy of carboplatin and ganetespib also holds Figures 7a and b) or BG-1 cells (Figures 7c and d) were subcutaneously injected into immunocompromised SCID SHO mice to grow tumors. Notably, although tumor growth was partially inhibited in mice treated with carboplatin or ganetespib alone, compared with vehicle treatment, the combined treatment led to complete tumor growth stagnation or even tumor regression (Figures 7a and c) . Importantly, a single dose of carboplatin combined with ganetespib was sufficient to induce complete depletion of FancA, FancD2 and BLM in the tumor xenografts, accompanied by γH2AX accumulation and PARP1 cleavage (Figures 7b and d) . We cannot exclude though that H2AX phosphorylation may partially result from caspase activity, mediated by caspase-activated DNase (CAD) and DNA damage. 32 Chromosome fragmentation and cell death induced by combined drug treatment is rescued by ectopic FancA expression. The drop in FancA levels upon ganetespib treatment (Figures 6a and b) suggests that loss of FancA might be causal for the synergistic effect of ganetespib with carboplatin. In support, FancA overexpression rendered Ovcar-5 cells considerably more resistant to both drugs, and this protective effect was most pronounced when ganetespib and carboplatin were used in combination (Figure 8a) . Moreover, the synergism between the two drugs was no longer observed upon FancA overexpression. The levels of overexpressed FancA could not be abrogated by ganetespib and/or carboplatin treatment, presumably because such high amounts of FancA no longer depend on HSP90 (Figure 8b ). The accumulation of phospho-H3 and γH2AX on treatment with drug combination was reduced, suggesting restored DNA repair capability in these cells (Figure 8b ). Most impressively, FancA overexpression in Ovcar-5 and EFO-21 cells largely prevented the massive accumulation of chromosome fragments during mitosis (Figure 8c ). In contrast, the amount of detectable crosslinked chromosomes was moderately decreased by FancA in carboplatin-treated cells. However, this was not seen in cells treated by the drug combination ( Supplementary Figures S8A and B) , presumably because some ICLs remained unrepaired but no longer gave rise to DNA breaks. Taken together, these results indicate that FancA is a crucial HSP90 client in the context of ovarian cancer cell survival after carboplatin treatment.
The nuclease DNA2 is required for chromosome fragmentation upon combined treatment with ganetespib and carboplatin. We showed that the drug combination triggers global chromosome fragmentation at least in large part owing to abrogation of the FA DNA repair pathway. ICL repair by the FA pathway also involves multiple DNA nucleases. Thus, depletion of FA core proteins can trigger uncontrolled resection of DNA. 19, 33 In particular, isolated depletion of FancD2 is known to induce over-resection of DNA by the helicase/nuclease DNA2 (albeit not chromosome condensation). 33 Thus, we tested whether DNA2 knockdown could overcome chromosome fragmentation in ganetespib/carboplatin-treated ovarian cancer cells. Indeed, stable depletion of DNA2 (Supplementary Figure S9A) led to near-complete recovery of the chromosome structure (but did not abolish the formation of detectable crosslinks), as shown by chromosome spread analyses of Ovcar-3 (Figure 9a Figure S9C, compare lanes 4 and 8) . Hence, the fragmentation of DNA in response to ganetespib/ carboplatin treatment can be explained by loss of FA pathway components leading to the unscheduled persistence of nuclease DNA2 activity.
Discussion
Here we show that the HSP90 inhibitor ganetespib synergizes with carboplatin in the effective destruction of ovarian cancer cells. Mechanistically, this drug combination induces severe DNA damage due to depletion of key elements of the FA repair pathway, causing cells to undergo massive chromosome fragmentation. The unrepaired cells continue unhindered along the cell cycle and aberrantly enter mitosis, followed by cell death (Figure 9c) . Thus, interstrand crosslinking of DNA combined with HSP90 inhibition induces an unusual and particularly effective kind of cell death, triggered by premitotic DNA fragmentation, in about 90% of cells in a broad panel of ovarian cancer cell lines, but not in non-transformed p53-proficient cells. Overall, these encouraging preclinical data might endorse the use of this drug combination to treat patients with newly diagnosed ovarian cancer. As carboplatin is already a standard therapy in first line, we propose to combine it with ganetespib as part of a 'hit hard and early' strategy, thereby hopefully avoiding or at least substantially delaying the emergence of platinumresistant cells.
Our results are in agreement with previous reports. Homologous recombination repair of double-stranded DNA breaks, as well as non-homologous end joining, are impaired by HSP90 inhibitors, enhancing radiosensitivity of tumor cells. [34] [35] [36] [37] Moreover, HSP90 inhibitors interfere with DNA damage signaling by degrading ATR, Chk1 and Rad51. Table S1 ) in the presence of 20 μM zVAD. The cells were processed as in Figure 4a and representative images are shown. The extent of chromosome fragmentation per cell was analyzed by counting the fragments in 10 randomly chosen metaphases. Significance was determined by the Student's t-test and the P-value is shown by asterisks (***P-valueo0.001) 25, 41, 42 In this scenario,
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High ex. the cells enter mitosis despite being far away from having completed DNA replication. 43 In contrast, we did not observe premature mitosis upon combined treatment with carboplatin and ganetespib (Figures 3a and c) , despite the depletion of Chk1 and Wee1 by the HSP90 inhibitor (Figure 3b) . The frequency of ICLs on treatment with a medically relevant concentration of carboplatin is relatively rare, that is, generating less than 1000 ICLs per cell. 44 Thus, we assume that the vast majority of cellular DNA can still be replicated despite the futile attempts of repairing the ICLs.
Ganetespib Carboplatin Combination
The absence of a functional FA pathway has long been known to sensitize ovarian cancer cells towards crosslinking agents. 45 Pharmacological inhibition of FA components prolongs the persistence of phosphorylated H2AX, 46 suggesting accumulation of DNA breaks. Importantly, however, condensed chromatin fragments were not described in this scenario, likely owing to intact G2/M checkpoint function. Thus, HSP90 inhibition may be even more effective in sensitizing cells towards platinum compounds.
DNA damage normally prevents the onset of mitosis. This is mediated at least in part through p53 activation and G2 arrest (G2/M checkpoint). It is therefore significant that up to 70% of all ovarian cancers 47 and over 90% of high-grade serous ovarian cancers 48 carry mutations in p53, which is also true for most of the cell lines studied here. Thus, the futile attempt to undergo mitosis may contribute to the selectivity of the carboplatin/ganetespib drug combination for cancer versus normal cells. In support, the p53-proficient cells did not undergo apoptosis in response to the combined treatment, whereas targeted deletion of p53 restored treatment efficacy (Supplementary Figure S1) .
The dramatic chromosome fragmentation observed with the drug combination requires DNA2 activity. It appears that ganetespib induces an imbalance between DNA synthesis in the context of repair and the removal of damaged DNA by nucleases. Thus, DNA2 nuclease activity and its independence of HSP90 contribute to the catastrophic response to the drug combination. In general, the cells require DNA2 for repression of replicative stress. DNA2 can trigger proper intra-S-phase checkpoints, 49 prevent replication fork reversal, 50 and restart replication when forks have already undergone reversal. 51 However, in response to ICL-inducing agents, DNA2 contributes to over-resection of DNA due to an imbalanced hyperactivation of its nuclease activity in response to loss of FancD2 and/or to impairment of the replication fork stabilizer BOD1L. 33, 52 These considerations are in line with our observation of phospho-RPA32 accumulation (Figure 2c ), a marker for ssDNA intermediates and DNA resection, as phospho-RPA recruits DNA2 to chromatin. 53, 54 Interfering with DNA repair as a means of tumor cell chemosensitization has long been proposed as a promising anticancer strategy. 55, 56 However, the development of specific inhibitors of DNA repair factors is far from being trivial. Moreover, targeted inhibitors always bear the risk of resistance development, either by compensatory mutations within the target itself, or by activation of alternative repair pathways. The advantage of HSP90 inhibitors may lie precisely in their pleiotropic activity. 7 The dual inactivation of ICL repair and cell cycle checkpoints, but not nucleases, by HSP90 inhibition results in a highly effective chemosensitization. Overall, this paper represents strong preclinical evidence to open the door towards designing first-line clinical trials with the combination.
Materials and Methods
Cell culture and treatment. Human EFO-21, Ovcar-3 and BG-1 cells were a gift from Carsten Gründker (UMG, Göttingen). Ovcar-5 cells that contain an RFP expression cassette were purchased from Cell Biolabs. Skov-6, Hoc-7, Skov-3 and A2780 cells were obtained from the German Collection of Cell lines (DSMZ, Braunschweig, Germany). Kuramochi, Cov318 and Snu-119 cells were obtained from Hagen Kulbe (Charité, Berlin, Germany); Cov434 and Cov362 cells were purchased from Sigma-Aldrich (Taufkirchen, Germany); ES-2 cells were a gift from Hermann Lage (Charité Berlin); and EFO-27 cells were purchased from the DSMZ. RPE-Tert and MCF10a cells were purchased from ATCC, (Virginia, USA). Ovcar-3, A2780, Snu-119 and Kuramochi cells were maintained in RPMI medium. All the other cell lines were maintained in Dulbecco's modified Eagle's medium. Cell culture media were supplemented with 10% fetal bovine serum and antibiotics. The cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 . For the treatment of cells, ganetespib (50 mM, Synta Pharmaceuticals, Lexington, MA, USA), zVAD (Z-VAD-FMK, 40 μM in DMSO, Enzo, Lausen, Switzerland), neocarzinostatin (NCS, 0.5 mg/ml, Sigma-Aldrich), paclitaxel (10 mM in DMSOSigma-Aldrich), mitomycin C (2 mM in DMSO, Sigma-Aldrich), cisplatin (1 mg/ml, Teva GmbH, Ulm, Germany) or carboplatin (10 mg/ml, Actavis, Luxembourg) were diluted in pre-warmed medium and added to the cells for the indicated periods of time.
Stable transduction and transfection. For stable knockdown of DNA2 in cell lines, HEK293T cells were co-transfected with lentiviral packaging vectors (pMD2.G from Addgene, Teddington, UK and pCMV-R8.91 from Plasmid Factory, Bielefeld, Germany) and the GIPZ-shDNA2 plasmid (V2LHS90523) or a GIPZ control plasmid (RHS4348; both from Dharmacon, Lafayette, CO, USA). Ovcar-3 and Ovcar-5 cells were transduced with the generated lentivirus in the presence of 8 μg/ml polybrene. To generate knockdown cells that contain shRNA, the plasmids plko-p53kd_1 (TRCN0000003753), plko-p53kd_2 (TRCN0000003755) or a plko control plasmid containing shRNA against luciferase (all plasmids from Dharmacon) were co-transfected with packaging vectors into HEK293T cells to generate vectorcontaining supernatant. A2780 cells were transduced with these vectors in the presence of polybrene, followed by selection with 1 μg/ml puromycin. Quantitative mRNA analysis by qRT-PCR. Total RNA was isolated using TRIzol (Invitrogen), followed by DNase I digest (Thermo Fisher Scientific, Darmstadt, Germany) and reverse transcription with Moloney Murine Leukemia Virus reverse transcriptase and random hexamer primers (Thermo Fisher Scientific). Maxima SYBR Green master mix (Thermo Fisher Scientific) was used for real-time PCR. The primer sequences for DNA2 were DNA2forward: 5′-ACCCAACAATCCTGTTTGTTTCC-3′ and DNA2reverse: 5′-TCCTCCTACATCA TCCCTAAGC-3′. PCR conditions were as follows: initial denaturation 15 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 45 s. Gene expression levels were normalized to ActinB as reference gene (actin_forward: 5′-CGACAGGCTGCAGAAGGAG-3′, actin_reverse: 5′-GTACTTGCGCTCAAGAGG AG-3′) and calculated using the 2 -ΔΔCt method. Depicted is the mean ratio, normalized to control knockdown cells.
Immunoblot analysis. The cells were harvested in protein lysis buffer (20 mM TRIS-HCl pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1 mM betaglycerophosphate, 2 M urea, protease inhibitor cocktail, Roche, Mannheim, Germany). After 10 min lysis on ice, the samples were briefly sonicated to disrupt DNA-protein complexes. Total protein concentration was measured using a Pierce BCA Protein assay kit (Thermo Fisher Scientific). After boiling the samples in Laemmli buffer at 95°C for 5 min, equal amounts of protein samples were separated by SDS-PAGE, transferred onto nitrocellulose, and visualized with the following antibodies: PARP1 (9542, Cell Signalling, Frankfurt, Germany), phosphoKap1/pKap1 (Ser824; ab70369, Abcam, Cambridge, UK), γH2AX (S139; 9718, Cell Signalling), phospho-RPA32/pRPA32 (Ser4/Ser8; A300-246A, Bethyl, Montgomery, USA), Hsc70 (sc-7298, Santa Cruz, Heidelberg, Germany), FancD2 (Santa Cruz), FancA, (A301-980A, Bethyl), BLM (A300-120A, Bethyl), β-actin (ab8227 Abcam), Wee1 (4936, Cell Signalling), phospho-Wee1/pWee1 (Ser642; 4910, Cell Signalling), Chk1 (2360, Cell Signalling), phospho-Chk1/pChk1 (Ser17; 2344, Cell Signalling), phospho-H3 (Ser10; 3377, Cell Signalling), p21 (2947, Cell Signalling), phospho-ATM (S1981; 4526, Cell Signalling), ATM (2873, Cell Signalling), ATR (2790, Cell Signalling), Chk2 (sc-5278, Santa Cruz), cyclin B1 (ab7260, Abcam) and DDB2 (sc-81256, Santa Cruz).
Determination of drug synergism. For determination of drug synergism, cell viability was assessed using the Cell TiterGlo Kit (Promega, Madison, WI, USA). Briefly, 1000-2000 cells were seeded 24 h before treatment. To determine the individual IC50 drug concentrations of carboplatin, ganetespib, neocarzinostatin, paclitaxel and mitomycin C, rising drug concentrations were applied for 72 h and relative cell viability was assessed by luminometry. Vehicle-treated control cells were set to 100% cell viability and the relative cell viability on drug treatment was calculated from three independent biological replicates for each drug concentration.
Drug synergism was assessed by treating cells with the single drugs at their IC25 and IC50 side by side with the combination of two drugs used at the same concentrations. Vehicle-treated cells were set to 100%, and the fraction affected (Fa) of each treatment was calculated by subtracting the relative remaining cell viability from DMSO control-treated cells. For calculating the Combination Index (CI), Fa values from single and combination treatments served as input using the Compusyn software. 21 CI values 41 describe antagonistic or non-synergistic effects of two drugs, CI = 1 indicates additive effects and CI values o1 correspond to synergistic effects of combined drug treatment.
Cell cycle analysis and mitotic index. For cell cycle analysis and determining the percentage of cells arrested in mitosis, the cells were collected after 24 and 48 h drug treatment (in the presence of 20 μM zVAD in case of 48 h treatment). The samples were fixed in ethanol and stained with propidium iodide and/or anti-phospho-H3 (Ser10). Cell cycle profiles were obtained by flow cytometry using the Guava system (Millipore, Darmstadt, Germany). For each condition, three independent biological replicates were processed, and all the samples were analyzed using the same gate settings.
Determination of apoptosis. Annexin V/7-AAD staining was conducted on living cells using the Nexin reagent (Millipore). The percentage of apoptotic cells were determined by flow cytometry using the Guava system (Millipore). For quantification of Annexin V-positive, or Annexin V/7-AAD double-positive cells, the same gate settings were applied for all the samples. For each experiment, at least three independent biological replicates were analyzed. Significance was calculated using Student's t-test.
Immunofluoresence, TUNEL staining and high-content microscopy. For immunofluorescence analysis, the cells were fixed with 4% paraformaldehyde for 30 min followed by permeabilization with 0.5% Triton X-100/ PBS. After 4 h incubation with antibodies against γH2AX (05-636, Millipore) or phospho-H3 (pH3, 3377, Cell Signalling) and extensive washing, the cells were stained with respective secondary antibodies (AlexaFluor488 and AlexaFluor546, Invitrogen) and nuclei counterstained with Hoechst 3342 (Roche). For single-cell analysis, the slides were assessed with a Zeiss AxioVert microscope. For quantification of γH2AX intensity and the number of pH3-positive cells, automated high-content microscopy was done using the Pathway HT Cell Imaging System and the AttoVision image acquisition software (Becton Dickinson, Heidelberg, Germany). Analysis was performed as previously described. 57 Briefly, fluorescence signals were normalized to Hoechst staining intensity, and the relative γH2AX signal and the percentage of pH3-positive cells were calculated. For each treatment group, at least three independent biological replica were analyzed. Significance was calculated using Student's t-test. For the assessment of cells with fragmented DNA, TUNEL staining (click-it TUNEL AlexaFluor488 imaging kit, Thermo Fisher Scientific) was applied on cells that had been treated with drugs for 48 h in the presence of the caspase inhibitor zVAD. The cells were co-stained with Hoechst solution and assessed using a Zeiss AxioVert microscope and × 20 objective.
Analysis of metaphase spreads. For analysis of chromosome structures, the cells were incubated for 48 h with the indicated drug concentrations in the presence or absence of 20 μM zVAD. Five hours before collection, 150 nM paclitaxel was added to enrich the population in mitotically arrested cells with condensed chromosomes. The cells were collected, swollen in a hypotonic solution (40% RPMI, 60% deionized H 2 O) for 20 min and then fixed using ice-cold Carnoy's fixative (3 : 1 acetic acid: methanol). After extensive washing with Carnoy's fixative, the cells were resuspended in 100% waterfree acetic acid and subsequently spread on slides, followed by staining with Giemsa solution (Carl Roth, Karlsruhe, Germany). Analysis was performed with a × 100 objective in oil on a Zeiss AxioVert microscope. For quantification of undamaged chromosomes, crosslinks or radials and chromosome fragments, 10 randomly chosen cells were analyzed per treatment group; for quantification of total cell numbers showing fragmented chromosome structures, 100 random cells per treatment group were counted.
Live-cell imaging. For live-cell analyses, Ovcar-5 cells were transiently transfected with H2B-GFP expressing plasmids using Lipofectamine 2000 and seeded on glass bottom dishes with four compartments (Greiner Bio-One, Germany). Twenty-four hours later, the cells were treated with ganetespib (20 nM) and/or carboplatin (50 μM) for 30 h. Subsequently, the cells were observed for 18 h by time-lapse microscopy at 37°C and 5% CO 2 using a DeltaVision ELITE microscope (GE Healthcare, NW, USA). Image stacks were recorded every 5 min using a PCO Edge sCMOS camera (PCO, Stuttgart, Germany) with a Z-optical spacing of 4 μm. The images were deconvoluted and further processed using the SoftWorx 6.0 (Applied Precision, Mississauga, Canada) software. 
